Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PAVLE REPOVIC

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1649437211
CMS profile
346691
Location
SEATTLE, WA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$74,585.35

75 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
Biogen, Inc. $25,497.15 22
Celgene Corporation $20,417.36 17
EMD Serono, Inc. $8,199.07 20
Genentech USA, Inc. $6,873.27 5
Alexion Pharmaceuticals, Inc. $6,375.00 5
Novartis Pharmaceuticals Corporation $4,347.50 3
GENZYME CORPORATION $2,076.00 2
Banner Life Sciences, LLC $800.00 1

Page 2 of 2; records 51–75 of 75 matching records. This page contains 25 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PAVLE REPOVIC

NPI 1649437211 · CMS profile ID 346691

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

SEATTLE, WA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–75 of 75 matching records. This page contains 25 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1649437211?year=2020&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PAVLE REPOVIC, NPI 1649437211, CMS profile ID 346691. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–75 of 75 matching records. This page contains 25 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1649437211?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). PAVLE REPOVIC, NPI 1649437211, CMS profile ID 346691. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–75 of 75 matching records. This page contains 25 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1649437211?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
PAVLE REPOVIC, NPI 1649437211, CMS profile ID 346691, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–75 of 75 matching records. This page contains 25 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1649437211?year=2020&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

75 matching records · $74,585.35 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 75 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–75 of 75.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
EMD Serono, Inc. $31.7201/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751272131 CMS
EMD Serono, Inc. $12.6101/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751272383 CMS
EMD Serono, Inc. $15.7701/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751272609 CMS
EMD Serono, Inc. $52.6001/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751272861 CMS
EMD Serono, Inc. $12.6201/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751273113 CMS
EMD Serono, Inc. $23.0101/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751273339 CMS
EMD Serono, Inc. $378.0101/25/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751298493 CMS
EMD Serono, Inc. $105.1601/25/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751298697 CMS
EMD Serono, Inc. $292.6701/24/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751270885 CMS
EMD Serono, Inc. $2.9001/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751271123 CMS
EMD Serono, Inc. $7.7201/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751271375 CMS
EMD Serono, Inc. $82.1701/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751271627 CMS
Biogen, Inc. $338.1001/11/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737277023 CMS
Biogen, Inc. $58.9301/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737277029 CMS
Biogen, Inc. $117.3301/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737277031 CMS
Biogen, Inc. $89.2101/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737277033 CMS
Biogen, Inc. $36.3101/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737277035 CMS
Biogen, Inc. $3.3001/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737277037 CMS
Biogen, Inc. $13.2201/11/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737277043 CMS
Biogen, Inc. $78.0001/11/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737277045 CMS
Biogen, Inc. $8,550.5001/11/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737277047 CMS
Biogen, Inc. $101.8801/10/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737277025 CMS
Biogen, Inc. $196.6401/10/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737277027 CMS
Biogen, Inc. $28.7201/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737277039 CMS
Biogen, Inc. $13.2201/10/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737277041 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $227,339.51 270
PY2020 $74,585.35 75
PY2021 $80,834.67 78
PY2022 $188,645.13 197
PY2023 $192,483.80 177
PY2024 $135,514.53 158
PY2025 $225,900.68 242

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $283.84 1
PY2025 Principal investigator $1,317,108.94 42
PY2024 Recipient $709.45 1
PY2024 Principal investigator $820,464.66 45
PY2023 Principal investigator $423,499.88 67
PY2022 Principal investigator $280,838.97 38
PY2021 Recipient $9,813.64 2
PY2021 Principal investigator $424,440.92 30
PY2020 Principal investigator $156,807.23 27
PY2019 Principal investigator $236,037.23 59

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

43 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Novartis Pharmaceuticals Corporation $3,689.10 12/17/2025 Non-covered Recipient Entity
SWEDISH MEDICAL CENTER
A Pilot Open-Label, Randomized, Multi-Center, Parall el-Arm, of Acute vs Delay Ofatumumab Treatment d uring an Acute Multiple Sclerosis Relapse No dispute reported 06/30/2026 1190313997
Principal investigator 1 Genentech, Inc. $842.40 12/16/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211556558
Principal investigator 1 Genentech, Inc. $743.85 12/16/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211556562
Principal investigator 1 Genentech, Inc. $2,090.00 12/03/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
OCARINA I No dispute reported 06/30/2026 1211556651
Principal investigator 1 Genentech, Inc. $3,691.04 12/01/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211556647
Principal investigator 1 Genentech, Inc. $987.00 11/19/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
OCARINA I No dispute reported 06/30/2026 1211556596
Principal investigator 1 Genentech, Inc. $551.00 11/19/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
OCARINA I No dispute reported 06/30/2026 1211556605
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $11,960.00 11/17/2025 Non-covered Recipient Entity
Bloodworks Northwest
A Phase 1, Multicenter, Single-arm, Dose-escalation Study Of CC-97540 (BMS-986353), CD19-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, Evaluating Safety and Tolerability in Participants with Autoimmune Neurological Diseases: Relapsing Forms of Multiple Sclerosis (RMS), Progressive Forms of Multiple Sclerosis (PMS), or Refractory Myasthenia Gravis (MG) (Breakfree-2) No dispute reported 06/30/2026 1235998592
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $325,039.20 11/17/2025 Covered Recipient Teaching Hospital
Swedish Medical Center
A Phase 1, Multicenter, Single-arm, Dose-escalation Study Of CC-97540 (BMS-986353), CD19-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, Evaluating Safety and Tolerability in Participants with Autoimmune Neurological Diseases: Relapsing Forms of Multiple Sclerosis (RMS), Progressive Forms of Multiple Sclerosis (PMS), or Refractory Myasthenia Gravis (MG) (Breakfree-2) No dispute reported 06/30/2026 1236000144
Principal investigator 1 Genentech, Inc. $1,024.08 11/14/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211556635
Principal investigator 1 GENZYME CORPORATION $3,790.00 11/04/2025 Covered Recipient Teaching Hospital
Swedish Medical Center
A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226142448
Principal investigator 1 Novartis Pharmaceuticals Corporation $5,403.00 10/29/2025 Covered Recipient Teaching Hospital
Swedish Medical Center
A Pilot Open-Label, Randomized, Multi-Center, Parall el-Arm, of Acute vs Delay Ofatumumab Treatment d uring an Acute Multiple Sclerosis Relapse No dispute reported 06/30/2026 1190296151
Principal investigator 1 Genentech, Inc. $9,258.00 10/28/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211556620
Principal investigator 1 Genentech, Inc. $3,491.00 10/28/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211556639
Principal investigator 1 Genentech, Inc. $1,598.00 10/28/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211556643
Principal investigator 1 Genentech, Inc. $9,467.75 10/27/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
AN OPEN-LABEL, SINGLE-ARM 4-YEAR STUDY TO EVALUATE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB TREATMENT IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS No dispute reported 06/30/2026 1211556549
Principal investigator 1 Genentech, Inc. $3,989.00 10/22/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
OCARINA I No dispute reported 06/30/2026 1211556624
Principal investigator 1 Genentech, Inc. $12,835.80 10/17/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211556553
Principal investigator 1 Genentech, Inc. $594.24 10/10/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211556628
Principal investigator 1 Genentech, Inc. $1,400.00 10/10/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211556632
Principal investigator 1 Genentech, Inc. $1,741.00 10/08/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
OCARINA I No dispute reported 06/30/2026 1211556573
Principal investigator 1 Genentech, Inc. $3,467.70 09/17/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211556546
Principal investigator 1 Genentech, Inc. $12,122.00 08/20/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
OCARINA I No dispute reported 06/30/2026 1211556617
Principal investigator 1 Genentech, Inc. $14,174.00 07/21/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211556612
Principal investigator 1 Genentech, Inc. $6,000.00 07/14/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
Phase III study of Satralizumab in AE No dispute reported 06/30/2026 1211556296
Principal investigator 1 Genentech, Inc. $8,440.00 06/25/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
Phase III study of Satralizumab in AE No dispute reported 06/30/2026 1211556293
Principal investigator 1 Genentech, Inc. $12,371.40 06/25/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211556541
Principal investigator 1 Genentech, Inc. $11,277.90 06/18/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211556566
Principal investigator 1 Genentech, Inc. $48,897.53 06/02/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211556577
Principal investigator 1 Genentech, Inc. $136.35 05/23/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211556569
Principal investigator 1 Genentech, Inc. $5,385.15 05/13/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211556592
Principal investigator 1 Genentech, Inc. $27,120.00 05/09/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211556609
Principal investigator 1 GENZYME CORPORATION $1,900.00 04/02/2025 Covered Recipient Teaching Hospital
Swedish Medical Center
A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226142397
Recipient F. Hoffmann-La Roche AG $283.84 03/31/2025 Covered Recipient Physician Roll Over Protocol ROP for WA21092 OPERA I WA21093 OPERA II and WA25046 ORATORIO studies No dispute reported 06/30/2026 1211538186
Principal investigator 1 Genentech, Inc. $952.20 03/05/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211556537
Principal investigator 1 Novartis Pharmaceuticals Corporation $208,436.20 02/19/2025 Covered Recipient Teaching Hospital
Swedish Medical Center
A Pilot Open-Label, Randomized, Multi-Center, Parall el-Arm, of Acute vs Delay Ofatumumab Treatment d uring an Acute Multiple Sclerosis Relapse No dispute reported 06/30/2026 1190296265
Principal investigator 1 Genentech, Inc. $28,663.00 02/14/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211556580
Principal investigator 1 Celgene Corporation $10,590.00 02/12/2025 Non-covered Recipient Entity
Bloodworks Northwest
A Phase 1, Multicenter, Single-arm, Dose-escalation Study Of CC-97540 (BMS-986353), CD19-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, Evaluating Safety and Tolerability in Participants with Autoimmune Neurological Diseases: Relapsing Forms of Multiple Sclerosis (RMS), Progressive Forms of Multiple Sclerosis (PMS), or Refractory Myasthenia Gravis (MG) (Breakfree-2) No dispute reported 06/30/2026 1222305606
Principal investigator 1 GENZYME CORPORATION $18,550.00 02/04/2025 Covered Recipient Teaching Hospital
Swedish Medical Center
A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226142390
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $123,441.93 01/27/2025 Covered Recipient Teaching Hospital
Swedish Medical Center
A Phase 1, Multicenter, Single-arm, Dose-escalation Study Of CC-97540 (BMS-986353), CD19-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, Evaluating Safety and Tolerability in Participants with Autoimmune Neurological Diseases: Relapsing Forms of Multiple Sclerosis (RMS), Progressive Forms of Multiple Sclerosis (PMS), or Refractory Myasthenia Gravis (MG) (Breakfree-2) No dispute reported 06/30/2026 1236000142
Principal investigator 1 Biogen, Inc. $100,240.12 01/22/2025 Covered Recipient Teaching Hospital
Swedish Medical Center
SARS-CoV-2 Vaccination in Individuals with Multiple Sclerosis treated with natalizumab, diroximel fumarate or ocrelizumab: An Observational Study on Immunogenicity and Safety No dispute reported 06/30/2026 1236947712
Principal investigator 1 Genentech, Inc. $1,500.00 01/08/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211556588
Principal investigator 1 Celgene Corporation $269,258.00 01/06/2025 Covered Recipient Teaching Hospital
Swedish Medical Center
A Phase 1, Multicenter, Single-arm, Dose-escalation Study Of CC-97540 (BMS-986353), CD19-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, Evaluating Safety and Tolerability in Participants with Autoimmune Neurological Diseases: Relapsing Forms of Multiple Sclerosis (RMS), Progressive Forms of Multiple Sclerosis (PMS), or Refractory Myasthenia Gravis (MG) (Breakfree-2) No dispute reported 06/30/2026 1222305670